mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals
Article
[키워드] 95% CI
ACE2
ACE2 Inhibition
addition
antibody
Antibody responses
Beta coronaviruses
binding
BNT162b2 vaccine
Breakthrough infection
characterized
contribute
cross-reactive
Defense
dose
healthcare worker
HKU1
human coronavirus
humoral
IgA
IgA response
IgG
IgG level
IgG response
immunoassay
individual
individuals
induce
infected with SARS-CoV-2
investigated
less
Meso Scale Discovery
mRNA
mRNA vaccination
mRNA vaccine
mucosal
mucosal immune
mucosal immunity
multiplex
naïve
neutralizing antibody
neutralizing response
neutralizing responses
neutralizing responses.
OC43
of BNT162b2
participant
Participants
pathogenic
plasma
positively correlated
profile
response
SARS-CoV-2
SARS-CoV-2 IgG
SARS-COV-2 infection
SARS-CoV-2-specific IgG
second dose
selected
sensitivity
Spearman
spike-specific IgG
Transmission
vaccination
vaccine dose
variants of concern
[DOI] 10.3389/fimmu.2022.953949 PMC 바로가기
[DOI] 10.3389/fimmu.2022.953949 PMC 바로가기